Emergency Reversal of Anticoagulation: Novel Agents

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2014 Jun 28

PMID 24969622

Citations 6

Authors

Michael Levine

Joshua N Goldstein

Affiliations

Soon will be listed here.

Abstract

Historically, oral anticoagulation involved the administration of vitamin K antagonists, such as warfarin. However, because of the need for frequent monitoring and the desire for safer anticoagulants, several novel oral anticoagulants have been developed. These newer agents include the factor Xa inhibitors (eg, rivaroxaban, apixaban, edoxaban), along with the direct thrombin inhibitors (eg, dabigatran). This manuscript provides a brief overview of their uses and mechanisms of action, along with a review of currently available evidence for reversal strategies when life-threatening bleeding occurs.

Citing Articles

Risk Factors for Pulmonary Embolism in ICU Patients: A Retrospective Cohort Study from the MIMIC-III Database.

Huang C, Hong C, Xu T, Zhao D, Wu Z, Chen L Clin Appl Thromb Hemost. 2022; 28:10760296211073925.

PMID: 35043708 PMC: 8796081. DOI: 10.1177/10760296211073925.

Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.

Kustos S, Fasinu P Medicines (Basel). 2019; 6(4).

PMID: 31618893 PMC: 6963825. DOI: 10.3390/medicines6040103.

Diagnosis and Management of Acute Intracerebral Hemorrhage.

Morotti A, Goldstein J Emerg Med Clin North Am. 2016; 34(4):883-899.

PMID: 27741993 PMC: 5089075. DOI: 10.1016/j.emc.2016.06.010.

New Oral Anticoagulants and Their Reversal Agents.

Morotti A, Goldstein J Curr Treat Options Neurol. 2016; 18(11):47.

PMID: 27696178 DOI: 10.1007/s11940-016-0430-5.

Anticoagulation drug therapy: a review.

Harter K, Levine M, Henderson S West J Emerg Med. 2015; 16(1):11-7.

PMID: 25671002 PMC: 4307693. DOI: 10.5811/westjem.2014.12.22933.

References

Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J . A specific antidote for dabigatran: functional and structural characterization. Blood. 2013; 121(18):3554-62. DOI: 10.1182/blood-2012-11-468207. View

Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson K, Stigendal L, Sten-Linder M . Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2010; 9(1):133-9. DOI: 10.1111/j.1538-7836.2010.04098.x. View

Lee C, Ansell J . Direct thrombin inhibitors. Br J Clin Pharmacol. 2011; 72(4):581-92. PMC: 3195735. DOI: 10.1111/j.1365-2125.2011.03916.x. View

van Ryn J, Stangier J, Haertter S, Liesenfeld K, Wienen W, Feuring M . Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103(6):1116-27. DOI: 10.1160/TH09-11-0758. View

Dinkelaar J, Molenaar P, Ninivaggi M, de Laat B, Brinkman H, Leyte A . In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. J Thromb Haemost. 2013; 11(6):1111-8. DOI: 10.1111/jth.12236. View

Garcia D, Barrett Y, Ramacciotti E, Weitz J . Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2012; 11(2):245-52. DOI: 10.1111/jth.12096. View

Ganetsky M, Babu K, Salhanick S, Brown R, Boyer E . Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011; 7(4):281-7. PMC: 3550194. DOI: 10.1007/s13181-011-0178-y. View

Gresham C, Levine M, Ruha A . Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose. J Med Toxicol. 2009; 5(4):242-9. PMC: 3550411. DOI: 10.1007/BF03178275. View

Kawano-Castillo J, Ward E, Elliott A, Wetzel J, Hassler A, McDonald M . Thrombelastography detects possible coagulation disturbance in patients with intracerebral hemorrhage with hematoma enlargement. Stroke. 2014; 45(3):683-8. PMC: 4115455. DOI: 10.1161/STROKEAHA.113.003826. View

10.

Hapgood G, Butler J, Malan E, Chunilal S, Tran H . The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost. 2013; 110(2):308-15. DOI: 10.1160/TH13-04-0301. View

11.

Kubitza D, Becka M, Roth A, Mueck W . Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008; 24(10):2757-65. DOI: 10.1185/03007990802361499. View

12.

Hankey G, Eikelboom J . Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011; 123(13):1436-50. DOI: 10.1161/CIRCULATIONAHA.110.004424. View

13.

Mackman N . The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009; 108(5):1447-52. PMC: 2838713. DOI: 10.1213/ane.0b013e31819bceb1. View

14.

Rupprecht H, Blank R . Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs. 2010; 70(16):2153-70. DOI: 10.2165/11538030-000000000-00000. View

15.

Bowry R, Fraser S, Archeval-Lao J, Parker S, Cai C, Rahbar M . Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke. Stroke. 2014; 45(3):880-3. PMC: 3954973. DOI: 10.1161/STROKEAHA.113.004016. View

16.

Vine A . Recent advances in haemostasis and thrombosis. Retina. 2008; 29(1):1-7. DOI: 10.1097/IAE.0b013e31819091dc. View

17.

Bhanwra S, Ahluwalia K . The new factor Xa inhibitor: Apixaban. J Pharmacol Pharmacother. 2014; 5(1):12-4. PMC: 3917159. DOI: 10.4103/0976-500X.124409. View

18.

Godier A, Miclot A, Le Bonniec B, Durand M, Fischer A, Emmerich J . Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2011; 116(1):94-102. DOI: 10.1097/ALN.0b013e318238c036. View

19.

Yee D, OBrien S, Young G . Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet. 2013; 52(11):967-80. DOI: 10.1007/s40262-013-0094-1. View

20.

Wheeler A, Rice T . Coagulopathy in critically ill patients: part 2-soluble clotting factors and hemostatic testing. Chest. 2010; 137(1):185-94. DOI: 10.1378/chest.08-2535. View